2021 tables: Institutions - life sciences - corporate

The 2021 tables are based on Nature Index data from 1 January 2020 to 31 December 2020.

Table criteria

# Institution Share 2019 Share 2020 Count 2020 Change in Adjusted Share 2019-2020*
1 AstraZeneca plc, United Kingdom (UK) 14.61 16.75 85 5.3%
2 GlaxoSmithKline plc. (GSK), United Kingdom (UK) 7.22 11.69 58 48.7%
3 Genomics England Ltd., United Kingdom (UK) 0.22 2.61 10 994.2%
4 Earlham Institute (EI), United Kingdom (UK) 1.10 1.88 18 57.7%
5 Immunocore Limited, United Kingdom (UK) 0.10 1.69 2 1,394.7%
6 Oxford Nanopore Technologies Ltd., United Kingdom (UK) 0.53 1.62 7 182.5%
7 Oxford Genetics Ltd., United Kingdom (UK) 0.85 1 N/A
8 Babylon Health, United Kingdom (UK) 0.83 1 N/A
9 Zoe Global Limited, United Kingdom (UK) 0.61 3 N/A
10 Crescendo Biologics Ltd., United Kingdom (UK) 0.46 2 N/A
11 Storm Therapeutics Ltd., United Kingdom (UK) 0.20 0.40 3 85.9%
12 Johnson Matthey (JM), United Kingdom (UK) 0.40 1 N/A
12 Burczyk/Faville/Kottler LTD., United Kingdom (UK) 0.40 1 N/A
13 Motac Neuroscience Ltd., United Kingdom (UK) 0.39 2 N/A
14 Isogenica Ltd., United Kingdom (UK) 0.15 0.38 1 123.9%
15 Cyber Espion Ltd., United Kingdom (UK) 0.33 1 N/A
15 Health Technology Wales (HTW), United Kingdom (UK) 0.33 1 N/A
15 ATDBio Ltd., United Kingdom (UK) 0.33 1 N/A
16 SYSTEMIQ Ltd., United Kingdom (UK) 0.29 1 N/A
17 Unilever, United Kingdom (UK) 0.17 0.28 3 53.1%
18 RxCelerate Ltd., United Kingdom (UK) 0.27 1 N/A
19 Scancell Holdings PLC, United Kingdom (UK) 0.26 2 N/A
20 Invicro, LLC, United Kingdom (UK) 0.24 0.25 3 -4.8%
21 AB Vista, United Kingdom (UK) 0.25 1 N/A
21 Retrogenix Ltd., United Kingdom (UK) 0.25 1 N/A
22 OMass Therapeutics Limited, United Kingdom (UK) 0.23 2 N/A
23 Proteome Sciences PLC, United Kingdom (UK) 0.23 2 N/A
24 Fluxus Technology Ltd., United Kingdom (UK) 0.21 1 N/A
25 NeuroGEARS Ltd., United Kingdom (UK) 0.20 1 N/A
25 Metrion Biosciences Ltd., United Kingdom (UK) 0.20 1 N/A
26 Lume VR Ltd., United Kingdom (UK) 0.15 1 N/A
27 Horizon Discovery Ltd., United Kingdom (UK) 0.05 0.14 2 163.6%
28 Cypex Limited, United Kingdom (UK) 0.14 1 N/A
29 Nightstar Therapeutics Ltd., United Kingdom (UK) 0.13 1 N/A
30 ARUP, United Kingdom (UK) 0.13 1 N/A
30 Southern Water Services Ltd., United Kingdom (UK) 0.13 1 N/A
30 Auxolytic Ltd., United Kingdom (UK) 0.13 1 N/A
30 Essen BioScience, Ltd., United Kingdom (UK) 0.13 1 N/A
31 Bath ASU, United Kingdom (UK) 0.12 1 N/A
32 Genomics plc, United Kingdom (UK) 0.19 0.11 4 -43.5%
33 Kymab Limited, United Kingdom (UK) 0.31 0.11 2 -68.4%
34 Immetacyte Ltd., United Kingdom (UK) 0.11 1 N/A
35 Heliopolis Biotechnology Ltd., United Kingdom (UK) 0.10 2 N/A
36 TauRx Therapeutics Ltd., United Kingdom (UK) 0.10 1 N/A
37 Ludger Ltd., United Kingdom (UK) 0.10 1 N/A
38 Microbiotica Limited, United Kingdom (UK) 0.13 0.09 2 -31.8%
39 PROWLER.io, United Kingdom (UK) 0.09 1 N/A
40 Xelect Ltd, United Kingdom (UK) 0.09 1 N/A
41 Juno Genetics Ltd., United Kingdom (UK) 0.08 1 N/A
42 LGC Limited, United Kingdom (UK) 0.07 1 N/A
43 Exscientia Ltd., United Kingdom (UK) 0.05 0.07 1 44.4%
44 Vodafone Group Plc., United Kingdom (UK) 0.07 1 N/A
45 Unit DX, United Kingdom (UK) 0.06 0.06 1 -2.4%
45 Bering Limited, United Kingdom (UK) 0.06 1 N/A
46 OrganOx Limited, United Kingdom (UK) 0.06 1 N/A
47 Autolus, Ltd., United Kingdom (UK) 0.09 0.06 1 -39.8%
48 IOTA Pharmaceuticals Ltd., United Kingdom (UK) 0.06 2 N/A
49 Apple Tree Partners, United Kingdom (UK) 0.06 1 N/A
49 Fluidic Analytics, Ltd., United Kingdom (UK) 0.06 1 N/A
49 Wren Therapeutics Ltd., United Kingdom (UK) 0.06 1 N/A
49 Cambridge Innovation Capital (CIC), United Kingdom (UK) 0.06 1 N/A
50 Edinburgh BioQuarter, United Kingdom (UK) 0.04 0.06 2 32.5%

Footnote

Each year, the Nature Index publishes tables based on counts of high-quality research outputs in the previous calendar year. Users please note:

  1. The data behind the tables are based on a relatively small proportion of total research papers, they cover the natural sciences only and outputs are non-normalized (that is, they don’t reflect the size of the country or institution, or its overall research output).
  2. The Nature Index is one indicator of institutional research performance. The metrics of Count and Share used to order Nature Index listings are based on an institution’s or country’s publication output in 82 natural-science journals, selected on reputation by an independent panel of leading scientists in their fields.
  3. Nature Index recognizes that many other factors must be taken into account when considering research quality and institutional performance; Nature Index metrics alone should not be used to assess institutions or individuals.
  4. Nature Index data and methods are transparent and available under a creative commons licence at natureindex.com.

The Nature Index database undergoes regular updating, corrections, adjustment of institutional hierarchies, and removal of retracted papers and thus the live website can differ from the frozen annual tables.

*The change in adjusted Share accounts for the small annual variation in the total number of articles in Nature Index journals. Share values have been adjusted to 2020 levels to calculate the percentage change. For more information on the adjustment, please see the Adjusted metric explainer.